Free Trial
NASDAQ:CADL

Candel Therapeutics (CADL) Stock Price, News & Analysis

$6.57
-0.72 (-9.88%)
(As of 07/17/2024 ET)
Today's Range
$6.35
$7.14
50-Day Range
$5.65
$14.00
52-Week Range
$0.66
$14.30
Volume
696,848 shs
Average Volume
2.79 million shs
Market Capitalization
$195.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Candel Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
67.4% Upside
$11.00 Price Target
Short Interest
Healthy
5.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Candel Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$253,844 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.20 out of 5 stars

Medical Sector

568th out of 915 stocks

Biological Products, Except Diagnostic Industry

96th out of 153 stocks

CADL stock logo

About Candel Therapeutics Stock (NASDAQ:CADL)

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

CADL Stock Price History

CADL Stock News Headlines

I’m giving you the name of this investment for free
What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.
Candel Therapeutics to Join Russell 3000® Index
Candel Reports Upbeat Data From Lung Cancer Study
I’m giving you the name of this investment for free
What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.
Candel Lights Up Investors' Portfolio With 830% Gain
See More Headlines
Receive CADL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
7/18/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CADL
Fax
N/A
Employees
42
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+67.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-37,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$120,000.00
Book Value
$0.44 per share

Miscellaneous

Free Float
17,378,000
Market Cap
$195.52 million
Optionable
Optionable
Beta
-0.95
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Paul-Peter Tak FMEDSCI (Age 63)
    M.D., Ph.D., President, CEO & Director
    Comp: $1.12M
  • Dr. Estuardo Aguilar-Cordova Inf. (Age 65)
    M.D., Ph.D., Founder & Director
    Comp: $35k
  • Dr. Francesca Barone M.D. (Age 46)
    Ph.D., Chief Scientific Officer
    Comp: $506.76k
  • Mr. Charles Schoch (Age 39)
    Interim CFO, VP of Finance & Corporate Controller
  • Dr. Seshu Tyagarajan Ph.D. (Age 56)
    Chief Technical & Development Officer
    Comp: $335.27k
  • Ms. Ileen B. Winick
    Chief People Officer
  • Ms. Susan Stewart J.D. (Age 63)
    L.L.M., Chief Regulatory Officer
  • Dr. William Garrett Nichols M.D. (Age 55)
    M.S., Chief Medical Officer

CADL Stock Analysis - Frequently Asked Questions

How have CADL shares performed this year?

Candel Therapeutics' stock was trading at $1.47 on January 1st, 2024. Since then, CADL shares have increased by 346.9% and is now trading at $6.57.
View the best growth stocks for 2024 here
.

How were Candel Therapeutics' earnings last quarter?

Candel Therapeutics, Inc. (NASDAQ:CADL) released its earnings results on Tuesday, May, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter.

When did Candel Therapeutics IPO?

Candel Therapeutics (CADL) raised $72 million in an initial public offering (IPO) on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

How do I buy shares of Candel Therapeutics?

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CADL) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners